ad04
Generic: ondansetron
ad04: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | Phase 3 |
FDA Decisions
FDA_MeetingFDA supported AD04 Phase 3 adaptive trial design, confirmed primary endpoint of zero heavy drinking days during months 5-6, and endorsed biomarker groups and interim analysis framework.(ADIL)
Frequently asked questions
Who is developing ad04?
ad04 is being developed by ADIAL PHARMACEUTICALS, INC..
What is ad04's latest FDA decision?
The most recent tracked FDA decision for ad04 is FDA_Meeting for FDA supported AD04 Phase 3 adaptive trial design, confirmed primary endpoint of zero heavy drinking days during months 5-6, and endorsed biomarker groups and interim analysis framework., dated July 29, 2025.
Get deeper analysis on ad04
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis